Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB1 | P15086 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5029251 | 0.83 | CPB1 (0.55) | CPB1ALDH1A1GAATACR1TSHR | |
| SCHEMBL5029505 | 0.81 | CPB1 (0.50) | CPB1ALDH1A1GAATSHRCYP3A4 | |
| SCHEMBL2987631 | 0.78 | CCR2 (0.55) | CPB1CYP2D6CCR2KCNH2 | |
| SCHEMBL2987634 | 0.78 | CCR2 (0.55) | CPB1CYP2D6CCR2KCNH2 | |
| SCHEMBL3737650 | 0.77 | ALDH1A1 (0.49) | CPB1ALDH1A1GAATSHRCTSK | |
| SCHEMBL3425012 | 0.77 | CCR2 (0.54) | CYP2D6CCR2KCNH2 | |
| SCHEMBL3425020 | 0.77 | CCR2 (0.54) | CYP2D6CCR2KCNH2 | |
| SCHEMBL3427504 | 0.77 | CCR2 (0.50) | CPB1CYP2D6CCR2KCNH2 | |
| SCHEMBL3427501 | 0.77 | CCR2 (0.50) | CPB1CYP2D6CCR2KCNH2 | |
| SCHEMBL3427499 | 0.77 | CCR2 (0.50) | CPB1CYP2D6CCR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | CPB1 764/4885ALDH1A1 827/4885GAA 4005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.